Slingshot Insights | Modis Therapeutics Overview

MODIS THERAPEUTICS Overview

Upcoming Projects (MODIS THERAPEUTICS)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (MODIS THERAPEUTICS)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (MODIS THERAPEUTICS)

Zogenix (ZGNX) acquiring Modis Therapeutics for its late-stage investigational medicine targeting Thymidine Kinase 2 deficiency (TK2d) that has received FDA Breakthrough Therapy and EMA PRIME designations
Tickers: ZGNX, Modis Therapeutics
Announcement Date: Sep 26, 2019
Zogenix (ZGNX) Makes Acquisition of Modis Therapeutics for its proprietary, late-stage investigational MT1621 targeting Thymidine Kinase 2 deficiency
Tickers: ZGNX, Modis Therapeutics
Announcement Date: Aug 26, 2019